Daniel Yokell

Vice President - Theranostic NeuroOncology Telix Pharmaceuticals

Seminars

Thursday 19th February 2026
Roundtable – Breaking Down Barriers in the Traditional Dogma of Drug Development for GBM to Overcome Delays in Bringing Combination Therapies to Patients
2:30 pm
  • How can the GBM field move beyond traditional IP models to foster collaboration for combination therapies?
  • How can the GBM community standardize preclinical models, data, and trial designs to prevent the wasteful duplication of work?
  • What changes are needed in trial design and regulatory pathways to overcome the delays in bringing combination therapies to market?
Wednesday 18th February 2026
Reconsidering the Design of Phase II/III Clinical Trials to Ensure Patients Overcome Challenges with Standard Control Arms for More Streamlined Trials
1:00 pm
  • Discussing strategies for molecular profiling and imaging biomarkers to successfully stratify patients for clinical trials
  • Exploring innovative control arms using AI and predictive measure to address budget constraints and patient recruitment challenges
  • Overcoming current standard of care involving toxic agents such as TMZ that might hinder the potential benefits of novel therapeutics
Wednesday 18th February 2026
Driving the Use of Biomarker-Based Enrollment in GBM trials to Accelerate Clinical Success & Improve Patient Outcomes
1:30 pm
  • Addressing the lack of analysis of molecular data in current enrolment protocols for GBM trials
  • Discussing strategies to incorporate biomarker-based enrolment given the rise of personalized therapies
  • Establishing the efficacy of targeted treatments in recurrent GBM to accelerate the delivery of peronalized therapies
Tuesday 17th February 2026
Advancing Imaging Techniques to Tackle Challenges Associated with Pseudo-progression & Pseudo-response in Glioblastoma Patients
8:00 am
  • Join this workshop to discuss best practices and future innovations in brain imaging to distinguish between pseudo-responses and real changes more effectively in GBMs
  • Exploring strategies to avoid serial brain biopsies GBM drug development to accurately assess dose selection and discover new biomarkers without invasive techniques
  • Discussing advanced neuroimaging strategies to address the challenges of high glucose uptake in the brain such as novel PET ligands that target GBM metabolic pathways beyond glucose
  • Evaluating the RANO assessment in modern GBM trials, focussing on how pseudo-progression and pseudo-responses can confound a drug’s true efficacy
  • Exploring novel and complementary assessment methods, such as volumetric analysis, advanced imaging biomarkers, and the integration of iRANO criteria for GBM immunotherapies, that can provide a more accurate and reproducible picture of tumor response
  • Addressing the practical challenges of standardizing new methodologies across different clinical sites and the regulatory considerations for their use as primary or secondary endpoints
Daniel yokell, speaking at 7th Glioblastoma Drug Development Summit